Hainan Huitong Biomedical Technology Co., Ltd

Primary objective: To study the pharmacokinetic parameters of the test and reference preparations when injected intramuscularly, and to evaluate the bioequivalence of the two preparations in humans, using fosphenytoin sodium injection (specification: 10 mL: 500 mg (calculated as C15H11N2NaO2)) developed by Hainan Huitong Biopharmaceutical Technology Co. as the test preparation (T) and fosphenytoin sodium injection (trade name: Cerebyx®, specification: 10 mL: 500 mg (calculated as C15H11N2NaO2)) licensed by Parke Davis Div Warner Lambert Co as the reference preparation (R). Secondary objective: To evaluate the safety of fosphenytoin sodium injection developed by Hainan Huitong Biopharmaceutical Technology Co. in healthy Chinese subjects.

Main purpose: To compare the differences in absorption degree and absorption rate between the sildenafil citrate orodispersible film (specification: 50 mg) provided by Hainan Huitong Biopharmaceutical Technology Co., Ltd. and the sildenafil citrate orodispersible film (trade name: Viagra®; specification: 50 mg) certified by Viatris Pharmaceutical Co., Ltd. in healthy Chinese people under fasting and postprandial administration conditions. Secondary objective: To evaluate the safety of sildenafil citrate orodispersible film (specification: 50 mg) provided by Hainan Huitong Biopharmaceutical Technology Co., Ltd. and sildenafil citrate orodispersible film (trade name: Viagra®; specification: 50 mg) certified by Viatris Pharmaceutical Co., Ltd. in healthy subjects under fasting and postprandial conditions. To evaluate the palatability of sildenafil citrate orodispersible film in healthy Chinese people and provide a basis for the taste of sildenafil citrate orodispersible film.

Main objective: The fasting trial adopted a single-center, randomized, open, single-dose, four-period completely repeated crossover design, and the postprandial trial adopted a single-center, randomized, open, single-dose, two-period crossover design to compare the differences in absorption degree and speed between the carbidopa-levodopa sustained-release tablets (specifications: each tablet contains 50 mg carbidopa and 200 mg levodopa) produced by Hunan Jiudian Pharmaceutical Co., Ltd. and the carbidopa-levodopa sustained-release tablets (specifications: each tablet contains 50 mg carbidopa and 200 mg levodopa; trade name: Sinemet®/Xining®) certified by MSD Pharma (Singapore) Pte. Ltd. in healthy people. Secondary objective: To evaluate the safety and tolerability of carbidopa-levodopa sustained-release tablets (specifications: each tablet contains 50 mg carbidopa and 200 mg levodopa) produced by Hunan Jiudian Pharmaceutical Co., Ltd. and carbidopa-levodopa sustained-release tablets (specifications: each tablet contains 50 mg carbidopa and 200 mg levodopa; trade name: Sinemet®) certified by MSD Pharma (Singapore) Pte. Ltd. under fasting and postprandial conditions.